Silencing of Peroxiredoxin-4 in Anticancer Activity of Gamma-Tocotrienol by Aznan, Afiah Nasuha & Jubri, Zakiah
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Silencing of Peroxiredoxin-4 
in Anticancer Activity 
of Gamma-Tocotrienol
Afiah Nasuha Aznan and Zakiah Jubri
Abstract
Peroxiredoxin-4 (PRDX4) is known to have a role in protecting cells from 
oxidative stress. It has been previously reported to increase in HepG2 liver cancer 
cells treated with gamma-tocotrienol (GTT). As GTT treatment potentially kills the 
cancer cell by regulating multiple signaling pathways, this study aims to determine 
the involvement of PRDX4 in GTT anticancer activity by silencing the PRDX4 
gene. The efficiency of PRDX4 silencing is achieved by optimizing HepG2 cell 
density, effect of serum presence in transduction media, incubation time of the 
cells with lentivirus, polybrene concentration, puromycin dose, functional titer, 
and multiplicity of infection (MOI) of the lentivirus. Silenced HepG2-PRDX4 cells 
(HepG2-shRNA-PRDX4) were treated with 70 μM of GTT for 48 h. GTT treatment 
significantly decreased the HepG2-shRNA-PRDX4 cell viability, increased apoptosis 
rate, and reduced free radical production compared to untreated HepG2-shRNA-
PRDX4 cells. These findings are further supported by proteomic analysis, which 
showed that pro-apoptotic and DNA damage proteins were upregulated, and 
proteins involved in cell cycle arrest, carcinogenesis, and anti-apoptotic signaling 
pathways were downregulated in HepG2-shRNA-PRDX4 cells treated with GTT 
compared to control. In conclusion, PRDX4 plays a role in GTT anticancer activity 
by increasing free radical production and oxidative damage to induce apoptosis in 
HepG2 cell.
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1. Introduction
Peroxiredoxin-4 (PRDX4) is one of the unique isomers of peroxiredoxin (PRDX) 
and is located in the endoplasmic reticulum. It has a peroxidase site to oxidize 
hydrogen peroxide (H2O2) and thus functions as an antioxidant, increases cell pro-
liferation, and is involved in regulating multiple signaling transduction pathways 
[1, 2]. Double cysteine residues at the peroxidase site of PRDX4 oxidize H2O2 and 
form water molecule. Oxidation is one of the processes that control H2O2 homeo-
stasis in the cells and thus indirectly reduces the risk of high level of oxidative stress 
[3]. The increase in reactive oxygen species (ROS) production in the tumor cells 
has been linked to increased PRDX4 expression, which makes the cell susceptible 
toward apoptosis [4]. Besides that, PRDX4 is a potential tumor biomarker [5] 
because of its high expression in most of the tumor tissues as it plays a role in tumor 
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growth and progression. The pattern of PRDX4 gene expression is different among 
cancer cells and depends on its role. PRDX4 gene may be involved in increasing 
the immune system of a normal cell to kill the cancer cells or reducing the level of 
oxidative stress to make the cancer cell more insusceptible toward the anticancer 
activity. PRDX4 gene expression is high in hepatocellular, pancreas, colon, and 
prostate cancer cells, whereas its expression is low in the lung, kidney, and thymus 
cancer cells [6]. Recent findings have shown that PRDX4 gene is highly expressed in 
HepG2 liver cancer cells treated with gamma-tocotrienol (GTT) [7] and reduces the 
HepG2 viability [8]. However, currently, there are no studies yet that focus on the 
role of PRDX4 in GTT treatment.
GTT is one of the tocotrienol isomers of vitamin E. It has an unsaturated and 
short phenyl chain and is differentiated based on the methyl group located on 
the chromanol ring [9]. This structure enables GTT to pass through the saturated 
lipid bilayer membrane and to be absorbed by the cells efficiently. GTT and other 
tocotrienol isomers are renowned as antioxidants [10]. Besides that, GTT has also 
been proven to have the capability as a signaling molecule to induce anticancer 
mechanism through activation of multiple pathways [11]. Previous studies have 
shown that GTT has an effective antitumor activity compared to other tocotrienol 
isomers [12]. GTT as an anticancer agent is selective on malignant cells, is capable of 
targeting multiple signaling pathways simultaneously, and has a synergistic effect 
with chemotherapy [13, 14]. Hence, various studies have been done to identify GTT 
capabilities and its mechanism in anticancer activities.
To determine the role of PRDX4 in anticancer activity of GTT, PRDX4 gene in 
HepG2 cells was silenced using lentivirus particles that carry the RNA sequence 
of PRDX4 gene (shRNA-PRDX4). The shRNA-PRDX4 is complementary with the 
PRDX4 gene sequence in the HepG2 cell. The PRDX4 gene and protein expression 
was reduced and indirectly caused the genotypic and phenotypic changes in the cell 
[15]. The silenced HepG2 cells were resistant toward puromycin and also encoded 
green fluorescent protein (GFP). Puromycin resistance enabled the culture of only 
silenced cell in the media. The presence of GFP as a reporter gene that exhibits 
bright green fluorescence when exposed to ultraviolet light was used as a visual 
tag for the expression of other genes. To silence the gene using lentivirus, there are 
several critical factors to be considered to avoid false positive and to increase silenc-
ing efficiency [16]. In this study, the silenced HepG2 cells were treated with GTT 
for 48 h. Then, cell viability, apoptosis rate, and ROS production were determined. 
Protein profiling was done to further confirm the proteins involved in the pathways.
2. Gene silencing
Gene silencing is used to study the role of specific genes by introducing anti-
sense RNA to block the translation of messenger RNA (mRNA) and inhibit gene 
expression or translation. This biological process is known as RNA interference 
(RNAi). RNA plays a role as a mediator in regulating gene expression. In relation to 
this, synthetic RNAi is developed to mimic the targeted gene and reduce its expres-
sion [17]. The silencing possibly occurs during the transcription or translation 
phase. When the targeted gene is silenced, its expression is reduced to 70% without 
eliminating the whole expression [18]. This technique offers one step forward for 
the therapeutic strategy of specialized medication for patients to undergo treatment 
for cancer or infectious diseases [19].
There are three types of RNAi which are small interference RNA (siRNA), 
microRNA (miRNA), and small hairpin RNA (shRNA). siRNA is a double-stranded 
RNA comprising 20–25 nucleotides. siRNA sequences are coupled with a polymer 
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and liposome carrier to enter the cell by using exogenous mechanism to silence the 
gene [20]. This process is known as transfection. shRNA is encoded specific RNA 
transcription which comprises 19–29 nucleotides. These nucleotides form a bridge 
for small hairpin of nine nucleotides [21]. shRNA silencing mechanism is known as 
transduction. The delivery of shRNA to the cell is through vectors such as plasmid, 
adenovirus, lentivirus, or retrovirus with a U6 promoter to regulate shRNA expres-
sion [22]. The vector will ensure that shRNA is expressed to silence the targeted 
gene. The silenced gene is inherited by the daughter cells [23]. miRNA is single-
stranded RNA (ssRNA) which comprises 21–23 nucleotides. This type of RNAi is 
complementary with mRNA molecule and can be used to silence the gene [24].
In vivo studies have shown that RNAi silences the targeted gene without affect-
ing other cellular activities such as interferon action which may inhibit protein 
synthesis [25]. siRNA can only be used in actively dividing cells and the silenc-
ing effect is temporary. This is because siRNA concentration decreases when the 
silenced cell divides. siRNA is also limited to cells with low susceptibility toward a 
foreign molecule [26]. In relation to this, the improvement of transfection method 
is required by introducing shRNA, which is able to silence the targeted gene in a 
more specific and effective way. In comparison to siRNA, shRNA and its lentivirus 
vector have the ability to stably integrate into the host genome. The silencing effect 
is passed to the daughter cell, resulting in permanent gene silencing. It increases the 
potential of the targeted gene to be silenced in nondividing cells, and the silencing 
effect can be delivered to cells that have low susceptibility toward lipid penetration. 
Thus, it can be applied in cell and animal model [27].
Both siRNA and shRNA have the same silencing mechanism; however, the 
choice of RNAi method to be used depends on the cell type, the time required 
to silence the gene, and the duration to silence the gene whether temporarily or 
permanently. The lentivirus plasmid used in this study has a GFP sequence, which 
functions as reporter gene, puromycin-resistance sequence for silenced cell selec-
tion, and a shRNA sequence that is antisense to the PRDX4 sequence. Thus, the 
percentage of transduced cells can be determined by viewing the cells under a 
fluorescent microscope and culturing the cells with an optimal dose of puromycin 
in the culture media to select for the silenced cells.
3. Mechanism of gene silencing
The purpose of gene silencing is to regulate gene expression by degrading the 
targeted gene’s product or reducing its mRNA translation through the delivery of 
RNAi agents into the cytoplasm [28]. Gene silencing mechanism involves both 
exogenous and endogenous pathways. The silencing mechanism of synthetic RNAi 
agents such as siRNA, shRNA, and miRNA is through the exogenous pathway, 
whereas the silencing mechanism for miRNA that exists naturally in the cell is 
through the endogenous pathway [29]. The mechanism of these three synthetic 
RNAi agents depends on the RNA-induced silencing complex (RISC) to cleave or 
degrade the mRNA of the targeted gene.
Further process of siRNA silencing occurs in the cytoplasm, whereas for 
shRNA and pre-miRNA, DNA integration occurs in the nucleus prior to the 
changes of pri-miRNA/pri-shRNA to the pre-miRNA/pre-shRNA [30]. The 
siRNA pathway is activated when dsRNA, together with the carrier complex, 
penetrates the cell membrane. Then, an endogenous dicer enzyme identifies the 
dsRNA sequence and splits it into small fragments of siRNA. The RISC complex 
binds to the siRNA fragments and causes RNA splitting for gene silencing to occur 
[31]. Plasmid carried by the lentiviral vector encodes the shRNA sequence of the 
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targeted gene and also shRNA transcripts on the promoter of RNA pol III or pol 
II. When the lentivirus infects the cells, lentiviral plasmids are transferred to the 
cytoplasm. An endogenous dicer enzyme identifies the plasmid and splits the 
shRNA into small fragments of pri-shRNA [32]. The small fragments of pri-
shRNA enter the nucleus, are multiplied by reverse transcription, and integrate 
into the host cell’s genome. The integrated genome will enter the shRNA silencing 
pathway to silence the gene.
Pre-shRNA and microRNA primers (pri-miRNA) are transcribed in the nucleus 
using a complex of Drosha microprocessors and DGCR8 as intermediators to 
produce the precursor microRNA (pre-miRNA)/pre-shRNA. Pre-miRNA/pre-
shRNA is then exported to the cytoplasm by exportin-5 and splits by a dicer enzyme 
to dsRNA [33]. The dsRNA is combined with RISC and is resolved by a helicase. 
The disassembled dsRNA activates the mRNA thread guide to recognize the target 
gene and Argonaute protein (Ago) in RISC [34]. The RISC complex helps to locate 
the mRNA thread guide which is complementary to the mRNA molecules of the 
targeted gene. The targeted gene’s mRNA is then degraded by the endonuclease and 
inactivated [35].
3.1 Critical factors of gene silencing
Each cell has a different level of susceptibility toward lentivirus infection, and 
this is the biggest challenge to overcome in order to achieve optimal conditions for 
successful transduction [36]. The efficiency of shRNA silencing on the targeted 
gene is measured manually by experiment. Therefore, several critical factors must 
be considered to achieve specificity and efficiency of cell transduction. The fac-
tors are cell density, polybrene concentration, serum presence in the transduction 
media, incubation time, and lentivirus and puromycin dosage [37]. Furthermore, 
the functional titer and the multiplicity of infection (MOI) should be determined 
so that the minimum amount of lentivirus needed to transduce the cell is used. 
The ideal shRNA structure and experimental design should also be taken into 
account [38].
3.2 Basic conditions of gene silencing
One of the basic conditions that needs to be optimized for successful gene 
silencing is the cell density. The recommended cell density for transduction is 
40–50% of cell confluence [16]. However, it depends on the size and growth rate 
of the cell. This confluence is to ensure that the cells have enough space to divide 
during transduction, which takes about 96 h. A previous study showed that cell 
confluence of more than 50% limits the interaction of lentivirus, cells, and DNA 
complex [39]. On the other hand, cell confluence of less than 30% will slow 
down cell growth [40]. Besides that, the cells used for transduction process must 
be active. This is because active cells take up foreign molecules more efficiently 
compared to quiescent cells.
The lentivirus membrane and cell wall are negatively charged. This causes 
difficulty for the lentivirus to infect the cell. Polybrene is a cation polymer that 
facilitates the lentivirus’s infiltration into the cells [41]. Higher concentration of 
polybrene results in a more effective lentiviral infection. However, if the concentra-
tion of polybrene is too high and it is incubated with the cells for a long duration, 
it may cause toxic effects to the cells [42]. Therefore, a polybrene concentration 
that does not affect cell viability in long culture periods was chosen as the opti-
mum condition. Studies have reported that the absence of serum in the culture 
media increases the efficiency of lentivirus DNA uptake by the cell [43]. However, 
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the absence of serum may affect cell growth. Therefore, the presence of serum 
in the media during the transduction process has to be determined for efficient 
transduction.
Stable silenced cells are selected through puromycin resistance. Non-transduced 
cells will die as puromycin inhibits protein synthesis [44]. Cells are cultured in 
media containing different concentrations of puromycin for 7 days. Then, a kill 
curve is constructed. The optimal dosage of puromycin to be used is the lowest dos-
age of puromycin that kills the cell significantly from the third to the seventh day. 
Cell viability is calculated starting from the third day because the cells only respond 
to the antibiotic exposure after 48 h.
Each cell type has different susceptibilities to lentivirus infection. Therefore, 
the functional titer needs to be determined in order to know the minimum 
lentivirus concentration required to infect the cell. Functional titer is the smallest 
transducing unit required for lentivirus to infect the cell. The transducing unit 
needs to be parallel to the ratio between the lentivirus and cell in culture, which is 
known as MOI. Functional titer and MOI are important to ensure optimum condi-
tion for shRNA expression for transduction to occur. Technically, only a small 
concentration of functional titer is required to transduce cells at a consistent MOI 
ratio [45]. MOI is the ratio of lentivirus that can infect the cell at one time. As the 
MOI increases, the lentivirus volume required in a fixed amount of functional 
titer also increases. The minimum MOI should be determined so that the optimum 
concentration of shRNA that is sufficient to infect the cells at the recommended 
confluence is used [46].
3.3 Small hairpin RNA (shRNA) design
The design of shRNA vector is important to control the optimum expression of 
shRNA. The optimum expression of shRNA is determined by the lentiviral vector, 
promoters, and shRNA structures [47]. A study reported that human cytomegalovi-
rus (hCMV) promoter is able to infect 95% of HepG2 cells and stably integrate into 
the host cell genome [48]. Lentivirus infection has low toxicity and does not affect 
the phenotype of the cell [49]. An efficient combination of promoter and vector will 
have an influence on the functional titer. Thus, shRNA can be expressed optimally 
to specifically silence a target gene.
3.4 Experimental design
A good experimental design is essential in gene silencing so that the silencing 
effect can be validated as specific silencing without any false positive. The recom-
mended experimental design for transduction method comprises a positive control, 
a negative control, and unsilenced cell [50]. The positive control is a sequence of 
normalized genes that are highly expressed in cells to identify whether the silenc-
ing have effects on the cell cycle or any pathways that may affect the growth of the 
silenced cells [51]. The presence of nontargeted lentivirus negative control (NTC) is 
to validate whether the plasmid of the lentivirus itself has an effect on the targeted 
gene expression. NTC is consists of shRNA sequence that is not complementary to 
any mammalian gene by having three or less nucleotide equivalents. It also contains 
GFP and also puromycin-resistance sequences. This control is important to avoid 
any false positive.
The NTC control should have no effect on the targeted gene and the trans-
duced cell [52]. The non-transduced cell controls are standardized to be compared 
with NTC controls. If the NTC and non-transduced cell controls show no dif-
ference in mRNA and protein expression of targeted proteins, this proves that 
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the plasmid carried by the lentivirus has no effect on the cell. Although shRNA 
functions are at the mRNA level, only changes in protein expression may con-
tribute to phenotypic changes. Therefore, validation of the mRNA and protein 
expression of the targeted proteins should be carried out to ensure that the gene 
expression is suppressed [53]. In addition, it is essential to validate the silencing 
effect by using more than two sequences of targeted gene shRNA. Every segment 
of gene sequence has a different effect in silencing the gene. The best sequence is 
selected based on the higher silencing rates shown through reduction of mRNA 
and protein expression of targeted gene.
4. Peroxiredoxin-4
4.1 Peroxiredoxin-4 and its function
H2O2 is produced during the disulfide bond formation in protein synthesis and 
from a side effect of cell biology mechanism located in the ER lumen and extracel-
lular matrix [54]. PRDX4 is localized in the endoplasmic reticulum and highly 
expressed in the pancreas, liver, and heart but is low in blood and brain leukocytes 
[5]. PRDX4 plays a role as an antioxidant by scavenging H2O2 and is a chaperone 
molecule to activate ER stress pathway [55]. PRDX4 is important for cell protection 
by reducing H2O2 to water in order to reduce oxidative stress.
In addition, PRDX4 has a role in regulating the activation of NF-ĸB transcrip-
tion factor and TNF-related apoptosis-inducing ligand (TRAIL) [56]. TRAIL is 
a transmembrane protein involved in apoptosis extrinsic pathway by binding to 
receptors DR4 or DR5. A reduction in PRDX4 expression leads to TRAIL activa-
tion and apoptosis induction, whereas an increase in PRDX4 expression inhibits 
the TRAIL activation and leads to cell survival [57]. The expression of PRDX4 in 
the cytosol increases NF-ĸB activity through phosphorylation of IκB-α [58]. 
Meanwhile, the expression of PRDX4 in the endoplasmic reticulum reduces NF-ĸB 
activity. NF-ĸB plays a role in cell proliferation and survival. A study has shown that 
PRDX4 is bound to the endothelium and is secreted when there is a redox change 
in the extracellular matrix [59]. This study is supported with the presence of high 
PRDX4 in the serum that indicates membrane leakage due to tissue destruction and 
cell apoptosis [60].
4.2 Mechanism of peroxiredoxin-4 as an antioxidant
PRDX4 triggers H2O2 signaling and protects cells from oxidative stress by oxidiz-
ing thioredoxin (Trx) proteins. Trx is a group of co-factor proteins with chaperone 
activity to control cell homeostasis and inhibit H2O2 signaling pathway [61]. PRDX4 
requires Trx peroxidase activity as an electron donor. The oxidized Trx is recycled 
by Trx reductase and NADPH as the primary electron donor. The main target 
of H2O2 molecules is two cysteine residues on PRDX4 to form catalytic peroxide 
mechanisms [62]. PRDX4 has two cysteine residues known as peroxidatic cyste-
ine residue (CysP-) and resolution cysteine residue (CysR-). These two cysteine 
subunits have peroxidatic properties to oxidize H2O2.
When the oxidative stress level is high, CysP- acts on peroxide to form sulfenic 
acid (CysP-SOH). CysP- is one of the cysteine units located near the N-terminal of 
PRXD4. CysP-SOH then reacts with another systemic subunit known as CysR- to 
form a stable disulfide bond, and water molecule is produced. Trx enzyme reduces 
the disulfide bond and completes the PRDX4 catalytic cycle by detoxifying the per-
oxide and producing an active thiol. If the oxidative stress keeps increasing, –SOH is 
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oxidized to –SO2H [63]. PRDX4 in -SO2H is reduced and re-oxidized by sulfiredoxin 
(Srx) through the reduction of ATP to ADP. This process is reversible [1]. However, 
in high oxidation state, –SO2H is continuously oxidized to –SO3H, and PRDX4 will 
undergo hyperoxidation. This will cause inhibition of oxidation, and PRDX4 will 
activate other pathways to counteract the oxidation state. In conclusion, PRDX4 
antioxidant activity is inhibited in high oxidation state and indirectly activates the 
ER-pressure pathway [64].
Studies have shown that the ER produces higher level of H2O2 than the mito-
chondria [65]. The main source of H2O2 in the ER lumen is the reaction of oxi-
dase-1 in the ER (Ero1) with disulfide isomerase protein (PDI) for disulfide bond 
formations during protein synthesis. The disulfide bonds are important to prevent 
the protein from degrading after it is excreted from the ER lumen. Disulfide 
bonds formation involves high oxidative processes, and the unfolded bonds on 
damaged proteins may cause unfolded protein response (UPR). Unfolded proteins 
are degraded by dissolution of disulfide bonds before the protein is bound to the 
cytosol membrane [66]. UPR is the action of cells to balance the increasing oxida-
tive stress and repair the function of or degrade the unfolded protein. The UPR 
will activate chaperone proteins of multiple pathways to balance the oxidative 
stress [67]. High oxidative stress in the ER will induce UPR and activate Ero1 to 
oxidize PDI catalytic enzymes by using oxygen molecules as the electron receiver 
[68]. The UPR action will form three intermediate sensors which are ATF6, IRE1α, 
and PERK and at the same time increase Ero1 and PRDX4 expressions as homeo-
static chaperones [69].
5.  The effect of viability, apoptosis rate, and reactive oxygen species 
production in HepG2 cell silenced with peroxiredoxin-4 and treated 
with GTT
Gamma-tocotrienol has been shown to have high antitumor activity [12] that 
exhibits cell cycle arrest and apoptosis in alveolar adenocarcinoma epithelial cells, 
A549 [70], and colorectal cancer cell HT-29 [71]. Its action is specific and causes the 
cancer cells to be more susceptible and sensitive to treatment [72]. A previous study 
by Sazli et al. [7] reported that PRDX4 was upregulated when HepG2 cells were 
treated with GTT. In this study, we silenced PRDX4 gene and treated with 70 μM 
of GTT to determine the role of PRDX4 in anticancer activity of GTT. Finding has 
shown that GTT treatment reduces HepG2-shRNA-PRDX4 cell viability signifi-
cantly (p < 0.01) compared to its control (HepG2-shRNA-PRDX4) and also com-
pared to HepG2 treated with GTT (p < 0.05) (Table 1). This viability assay is the 
first line of observation to show that GTT treatment does have an effect toward the 
silenced PRDX4 gene.
To investigate further the cause of reduction in cell viability, an apoptosis assay 
was done. The findings showed that the apoptosis rate was significantly increased 
(p < 0.05) in HepG2 treated with GTT compared to HepG2 control. Besides that, 
apoptosis rate increased in HepG2-shRNA-PRDX4-GTT (p < 0.05) compared to 
HepG2-shRNA-PRDX4 and HepG2-GTT (p < 0.05). GTT is capable to induce 
intrinsic and extrinsic apoptotic pathways in cancer cells such are breast cancer cell 
line, MCF-7, and MDA-MB-231 by increasing biomarker stress in the endoplasmic 
reticulum [73]. It is suggested that the main reason for the apoptosis in GTT-
treated group is high level of ROS production. GTT has triggered ROS production 
through PRDX4 activity. Studies reported that one of the anticancer activities of 
GTT is apoptosis induction through increases of ROS production [74]. We have 
postulated that GTT might trigger the ROS production through PRDX4 activity. 
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Hence, the level of ROS in each group was measured. The result showed that GTT 
increased ROS production (p < 0.05) in HepG2 group compared to the control 
but reduced ROS production in HepG2-shRNA-PRDX4 group. In HepG2-shRNA-
PRDX4, ROS production was even higher compared to other groups but causes no 
effect on the cell viability. This proves that the function of PRDX4 is to reduce ROS 
level and oxidative stress. GTT either increases ROS production [75] to stimulate 
apoptosis pathway in HepG2 group or directly activate the apoptosis pathway in 
HepG2-shRNA-PRDX4.
To investigate further, protein profiling was done using LCMS machine to detect 
proteins expressed in HepG2-shRNA-PRDX4 group treated with GTT compare with 
HepG2-shRNA-PRDX4 as its control group. Protein profiling has shown a total of 
3413 proteins expressed in HepG2-shRNA-PRDX4 and 3659 proteins expressed in 
HepG2-shRNA-PRDX4 treated with GTT. There are 2121 similar proteins expressed 
in both HepG2-shRNA-PRDX4 control group and HepG2-shRNA-PRDX4 treated 
with GTT. Statistical analysis has been done to differentiate protein which signifi-
cantly expressed HepG2-shRNA-PRDX4 treated with GTT compared to HepG2-
shRNA-PRDX4 control group using Fisher Exact test. The proteins are significantly 
expressed if the p value is less than 0.00398. Then, the significantly expressed 
protein is filtered and selected based on their functional processes that are involved 
in anticancer activity using UniProt and Reactome database.
There are 6 upregulated protein expressions that are CLU, NDRG1, NUDT2, 
PRDX5, RALB, and SLC25A6 (Table 2) and 14 downregulated proteins expres-
sion (Table 3) in HepG2-shRNA-PRDX4 group treated with GTT compared to 
HepG2-shRNA-PRDX4 control group. The downregulated protein expressions are 
EEF1A1, DHX9, PRDX1, RPS27, HIST2H2AA3, UBA52, UTP20, GSTP1, HSPB1 
NPM1, PRDX2, PRDX6, PRKDC, and TXN—the significant different expressed 
proteins involved in multiple anticancer mechanism targeted pathway. Most 
of the upregulated proteins are involved in apoptotic pathway and DNA dam-
age, whereas for the 14 downregulated proteins are involved in carcinogenesis 
pathway, anti-apoptotic, and cell cycle arrest. NDRG1, NUDT2, and PRDX5 
expressions resulted from cellular response on ROS production causes on the 
downstream action. Those proteins trigger cell cycle arrest due to DNA damage 
and apoptosis [76]. This situation worsens the cell conditions; thus, GTT has 
increased pro-apoptotic proteins to induce apoptosis. The apoptotic pathway 
is regulated by the expression of RALB, SLC25A6, and CLU which mediate the 
releases of cytochrome c from mitochondria [77].
Cell groups Cell viability (%) Apoptosis rate (%) Free radical production 
(arbitrary unit)
HepG2 100 ± 0.08 13.26 ± 1.97 1.00 ± 0.01
HepG2-shRNA-PRDX4 98 ± 12.33 18.91 ± 2.90 3.59 ± 0.33a
HepG2 with 70 μM GTT 90 ± 8.98 76.09 ± 4.89a 2.32 ± 0.09a
HepG2-shRNA-PRDX4 
with 70 μM GTT
63 ± 10.38b,c 92.65 ± 6.58b,c 1.61 ± 0.01b
The data is presented as the mean ± standard deviation. Each group consists of technical triplicate and three 
biological replicates. GTT, gamma-tocotrienol; PRDX4, peroxiredoxin-4; HepG2-shRNA-PRDX4, HepG2 cell with 
PRDX4 gene silenced.
aA significant difference compared to HepG2 group (p < 0.05).
bA significant difference compared to HepG2-shRNA-PRDX4 group (p < 0.01).
cA significant difference compared to HepG2 GTT-treated group (p < 0.05).
Table 1. 
The effect of GTT treatment on HepG2 and HepG2-shRNA-PRDX4 cell viability, apoptosis rate, and free 
radical production.
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The treatment of GTT on HepG2-shRNA-PRDX4 causes downregulated protein 
expression that is involved in cell cycle arrest, carcinogenesis pathway, proteins 
resulted in the ER stress, and anti-apoptotic. The level of ROS production was 
reduced in HepG2-shRNA-PRDX4 group treated with GTT, while the apoptosis 
activity was induced. EEF1A1, PRDX 1, PRDX2, PRDX6, and TXN are the proteins 
that function to reduce ROS level and thus become negative regulator for cell 
apoptosis [78]. Thus, GTT has shown to reduce the ROS accumulation in HepG2-
shRNA-PRDX4. GTT also suppressed the HIST2H2AA3, UBA52, and UTP20 
protein expressions that are involved in cell cycle arrest. The reduction of ROS level 
promotes cell proliferation [79], and this justifies the downregulation of protein 
expression for cell cycle arrest. The expression of DHX9 is downregulated, and it 
plays a role in regulating DNA repair. GTT in silenced cells reduces the ROS level 
and stimulates an apoptotic pathway to cause cell death.
GTT also suppressed PRDX1 and RPS27 expression that are involved in 
carcinogenesis. PRDX1 is a positive regulator of stress-activated MAPK cascade, 
whereas protein RPS27 is involved in JNK cascade and Wnt signaling pathway. 
The activation of ER stress response leads to the expression of protein that 
involves the MAPK pathway through the activation of JNK as mediator [80]. 
Most of the downregulated proteins are involved in direct negative regulator of 
apoptosis or negative regulator of oxidative stress-induced proteins. The proteins 
are GSTP1, HSPB1, NPM1, PRDX2, PRDX6, PRKDC, TXN, and UBA52. Protein 
profiling of HepG2-shRNA-PRDX4 showed that GTT induces apoptosis by reduc-
ing oxidative stress in the endoplasmic reticulum and upregulated pro-apoptotic 
protein expression.
Functional cluster/
protein name
Accession 
name 
(Swiss 
Prot)
P-value Fold 
change
Functional process Mechanism
Clusterin CLU 0.0013 1.0 Release of 
cytochrome c from 
mitochondria
Pro-
apoptosis
Protein NDRG1 NDRG1 0.0001 3.4 DNA damage 
response, signal 
transduction by 
p53 class mediator, 
cellular response to 
hypoxia
DNA 
damage
Bis(5′-nucleosil)-
tetraphosphatase
NUDT2 0.00056 8.5 Apoptotic process, 
cellular response to 
oxidative stress
Pro-
apoptosis
Peroxiredoxin-5, 
mitochondrial
PRDX5 0.0023 1.6 Apoptotic 
process, cell redox 
homeostasis, cellular 
response to reactive 
oxygen species
Pro-
apoptosis
Ras-related protein 
Ral-B
RALB 0.0020 4.8 Apoptotic process, 
cell cycle
Pro-
apoptosis
ADP/ATP 
translocase 3
SLC25A6 0.0003 1.4 Apoptotic process Pro-
apoptosis
Table 2. 
List of upregulated protein expression in HepG2-shRNA-PRDX4 treated with GTT compared to HepG2-
shRNA-PRDX4 control group.
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Functional 
cluster/protein 
name
Accession 
name (Swiss 
Prot)
P-value Fold 
change
Functional 
process
Mechanism
ATP-dependent 
RNA helicase A
DHX9 0.0015 0.80 Positive 
regulation of 
DNA repair
Carcinogenesis
Cluster of 
elongation factor 
1-alpha 1
EEF1A1 0.0001 0.80 Response to 
endoplasmic 
reticulum 
stress
ER stress
Glutathione 
S-transferase P
GSTP1 0.0001 0.60 Negative 
regulation 
of extrinsic 
apoptotic 
signaling 
pathway
Anti-apoptosis
Cluster of histone 
H2A type 2-A
HIST2H2AA3 0.0001 0.70 Negative 
regulation 
of cell 
proliferation
Cell cycle arrest
Heat shock 
protein beta-1
HSPB1 0.0001 0.70 Negative 
regulation 
of oxidative 
stress-induced 
intrinsic 
apoptotic 
signaling 
pathway
Anti-apoptosis
Nucleophosmin NPM1 0.0018 0.80 Negative 
regulation 
of apoptotic 
process
Anti-apoptosis
Peroxiredoxin-1 PRDX1 0.0001 0.60 Regulation 
of stress-
activated 
MAPK 
cascade, 
response to 
oxidative stress
Carcinogenesis
Peroxiredoxin-2 PRDX2 0.0001 0.70 Negative 
regulation 
of apoptotic 
process, 
response to 
oxidative stress
Anti-apoptosis
Peroxiredoxin-6 PRDX6 0.0001 0.60 Negative 
apoptosis 
regulation by 
regulating 
reactive 
oxygen species
Anti-apoptosis
DNA-dependent 
protein kinase 
catalytic subunit
PRKDC 0.0001 0.80 Negative 
regulation 
of apoptotic 
process
Anti-apoptosis
Cluster of 40S 
ribosomal 
protein S27
RPS27 0.0025 0.30 JNK cascade, 
Wnt signaling 
pathway
Carcinogenesis
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6. Conclusion
Gene silencing is a technique to prevent the expression of certain genes. This 
technique is very useful to study biochemical pathway or produce therapeutics to 
treat cancer and diseases. Optimizing on the basic criteria for gene silencing is very 
important to achieve efficient silencing. GTT treatment reduces cell viability and 
causes apoptosis in both silenced HepG2-shRNA-PRDX4 and non-silenced HepG2 
groups, but ROS production was increased non-silenced cells. The silencing of 
PRDX4 gene in HepG2 cells caused ROS accumulation but did not cause cell death. 
Proteomic technique showed that GTT caused HepG2 cell death through activation 
of multiple pathways. It either triggers the apoptosis pathway directly in silenced 
cell or increases ROS production through PRDX4 activity, thus increasing pro-
apoptotic and reducing anti-apoptotic protein expressions.
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Functional 
cluster/protein 
name
Accession 
name (Swiss 
Prot)
P-value Fold 
change
Functional 
process
Mechanism
Thioredoxin TXN 0.0001 0.01 Negative 
regulation 
of hydrogen 
peroxide-
induced cell 
death
Anti-apoptosis
Ubiquitin-60S 
ribosomal 
protein L40
UBA52 0.0011 0.70 Signal 
transduction 
by p53 class 
mediator 
resulting in cell 
cycle arrest, 
negative 
regulation 
of apoptotic 
process
Cell cycle 
arrest and 
Anti-apoptosis
Small subunit 
processome 
component 20 
homolog
UTP20 0.00010 0.20 Negative 
regulation 
of cell 
proliferation
Cell cycle arrest
Table 3. 
List of downregulated protein expression in HepG2-shRNA-PRDX4 treated with GTT compared to HepG2-
shRNA-PRDX4 control group.
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